Contracts › 75N93023F00002
75N93023F00002: Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus, Delivered By Nasal Spray
Awarded to The Johns Hopkins University by National Institutes of Health (NIH).
$3.6Mobligated
$3.6Mpotential value
30 June 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023F00002 |
|---|---|
| Vehicle | 75N93019D00031 |
| Awardee | The Johns Hopkins University |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN43 Health R&D Services; Health Care - Other; Experimental Development |
| Place of performance | MD |
| Period of performance | 05 May 2023 to 30 June 2028 |
| Potential end | 30 June 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record